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Culture is commonly regarded as the gold standard for 
diagnosis of Neisseria gonorrhoeae. However, nucleic 
acid amplification tests (NAATs) have rapidly replaced 
culture for diagnostics in many settings. The aim of the 
present study was to investigate the appropriate time for 
test-of-cure (TOC) when NAATs are used for diagnosis of 
gonorrhoea. In total, 30 patients (28 men and 2 women) 
provided urethral, cervical, rectal or pharyngeal speci-
mens for TOC. All included patients, except one who did 
not return for second TOC before day 19, tested negative 
within 2 weeks after treatment with cefixime 400 mg × 1. 
Antimicrobial susceptibility testing showed that 68% of 
the culture-positive strains were resistant to ciprofloxa-
cin. Thus, the recommended empirical treatment with 
ciprofloxacin in Norway should be changed immediately. 
TOC can be performed 2 weeks after treatment when 
NAATs are used for diagnosis of gonorrhoea. Key words: 
TOC; test-of-cure; N. gonorrhoeae; PCR; NAAT.
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Neisseria gonorrhoeae is the aetiological agent of go-
norrhoea, which is the second most prevalent bacterial 
sexually transmitted infection (STI) globally. Microscopy 
of urethral smears (Gram- or methylene-blue-stained) 
has a high sensitivity (≥ 95%) for symptomatic men. 
However, the sensitivity of microscopy in asymptomatic 
men or cervical samples is too low for reliable diag-
nostics (≤ 55%) (1). Culture has been regarded as the 
gold standard for diagnosis of gonorrhoea, but nucleic 
acid amplification tests (NAATs) have rapidly replaced 
culture due to, among other advantages, their improved 
sensitivity (2). 
However, NAATs do not allow antimicrobial suscepti-
bility testing. This is a major disadvantage, especially 
when the level of antimicrobial resistance in N. gonorr-
hoeae to all antimicrobials previously recommended as 
first-line treatment options is high (3–6). Furthermore, 
susceptibility to the currently recommended first-line 
treatment, extended-spectrum cephalosporins (ESCs) is 
declining globally (3, 4, 6). These ESCs, i.e. ceftriaxone 
(injectable) and cefixime (oral), are the last remaining 
treatment options in several settings. Using ceftriaxone, 
no treatment failure of urogenital gonorrhoea has yet 
been reported. However, verified treatment failures 
with cefixime, which is the standard treatment in many 
countries, have been reported in Japan since 2007 (7). 
Worryingly, the first 2 cases of failure outside Japan 
were reported recently in Norway (8). Test-of-cure 
(TOC) after provision of gonorrhoea therapy may soon 
be crucial in many settings. 
Appropriate evidence-based recommendations for the 
appropriate time for TOC using different NAATs for 
diagnosis of gonorrhoea is lacking. In contrast to some 
international guidelines (1, 9), which do not recommend 
TOC for uncomplicated gonorrhoea, if a recommended 
treatment has been given, in Norway TOC is recommen-
ded for all cases of gonorrhoea. This recommendation 
has been fortunate considering the reluctance to abandon 
ciprofloxacin as the recommended empirical treatment 
for gonorrhoea in Norway (10, 11). Currently a strictly 
validated in-house porA pseudogene polymerase chain 
reaction (PCR) (12, 13) is used extensively for diagnosis 
of gonorrhoea in Norway; nevertheless, the national 
recommendations for TOC are based on the time for 
TOC using culture, i.e. 7 days. 
The aim of the present study was to investigate the 
appropriate time for TOC when detection of N. gonorr-




A total of 257 consecutive patients with suspected genital and/
or extra-genital gonorrhoea attending an STI outpatient clinic 
(Olafiaklinikken) in Oslo, Norway were recruited from June 
2006 through January 2007. The 257 patients comprised 23 
women (mean age 31 years, range 15–46 years) and 234 men 
(mean age 33.7 years, range 15–73 years), where the majority 
(66.7%) was men having sex with men (MSM).
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The study was approved by the Regional Committee for 
Medical and Health Research Ethics (REK NORD) and each 
included participant provided written consent. 
Clinical samples 
Samples for PCR were collected using either a urethral flocked 
swab (Copan, brescia, Italy) or an endocervical flocked swab 
(Copan). The urethral swab was used for sampling the urethra. 
The endocervical swab was used for sampling the cervix, rectum 
and pharynx. Each sample was collected with individual swabs 
that were placed and transported in universal transport media 
– room temperature (UTM-RT; Copan) for PCR analysis. The 
samples for culture were consistently taken before the samples 
for PCR to avoid reducing the quality of the routine culture diag-
nostics. The sampling sites were chosen based on the medical 
history of each patient. Patients were asked to return after one 
week for a follow-up examination and TOC, and subsequently 
every week until two negative samples were deposited. In to-
tal, 669 clinical samples were collected from the 257 patients. 
Patients with positive samples who did not return for any TOC 
within 2 weeks were excluded from the study. 
Culture diagnostics 
Culture diagnostics were performed at Oslo University Hospi-
tal Ullevål, Oslo, Norway as part of their routine diagnostics 
by identification of characteristic colonies on selective cul-
ture medium according to standard laboratory procedures. For 
thorough species verification, oxidase test, identification of 
Gram-negative diplococci in microscopy, sugar utilization test, 
and Phadebact GC Monoclonal test (bactus Ab, Huddinge, 
Sweden) were used.
Antimicrobial susceptibility testing 
Determination of the minimum inhibitory concentrations (MICs, 
mg/l) of ceftriaxone, ciprofloxacin and spectinomycin was 
performed using the Etest method according to the instructions 
of the manufacturer (bioMérieux, Solna, Sweden). Interpreta-
tive criteria from the European Committee on Antimicrobial 
Susceptibility testing (EUCAST, www.eucast.org) were used.
DNA preparation 
All the UTM-RT samples were vortexed for 10 s and 200 µl 
sample were subsequently used for DNA preparation with the 
infectious disease protocol on the biorobot M48 workstation 
(Qiagen, Hilden, Germany), with an elution volume of 100 µl.
Real-time PCR
A real-time TaqMan FAST porA pseudogene PCR was per-
formed as previously described (12, 13), using 11.5 µl DNA 
template and 13.5 µl mastermix. All positive specimens were 
confirmed by repeated testing from a new DNA isolation. 
Antimicrobial treatment 
All patients except one were treated with cefixime 400 mg × 1 
(oral dose), despite the Norwegian recommendations of using 
ciprofloxacin for empirical treatment. The remaining patient 
was administered spectinomycin 2 g × 1 intramuscularly.
RESUlTS
A total of 50 gonorrhoea patients was identified. Eight 
of these patients were excluded because they did not 
return for any TOC, and 12 were excluded for returning 
later than 2 weeks after treatment for the first TOC. 
Accordingly, 30 patients who were N. gonorrhoeae 
positive, diagnosed by culture (n = 27) and/or NAAT 
(n = 30), in at least one clinical specimen were further 
examined. These 30 positive patients comprised two 
women (mean age 24.5 years, range 21–28) and 28 
men (mean age 37.4 years, range 22–58), of whom 
50% (n = 14) were MSM. Seven clinical specimens 
(representing different anatomical sites) from 7 patients 
were positive using NAAT, but negative with culture. 
Three of these patients (10% of all included patients) 
did not have any positive culture sample and, accor-
dingly, would have been reported falsely negative if 
not also NAAT was used for diagnostics. No patients 
were positive by culture only. Twenty-five patients 
were diagnosed with gonorrhoea at a single urogenital 
site, two patients had only extra-genital gonorrhoea 
(pharyngeal and rectal), and three patients had multiple 
infected sites (Table SI; available from http://www.
medicaljournals.se/acta/content/?doi=10.2340/0001
5555-1275). All patients diagnosed with urogenital 
gonorrhoea reported symptoms, such as discharge and 
dysuria, while all the extra-genital infections were 
asymptomatic. 
Nineteen patients (63%) returned for TOC within 
7 days (days 4 to 7) after treatment, and 16 (84%) of 
these were negative using NAAT. Two of the patients 
who remained positive (positive TOC on days 4 and 6) 
provided a negative sample within 14 days (day 11 for 
both patients). The remaining patient (positive TOC 
on day 7) did not return before day 19, but then had a 
negative TOC (Table SI; Fig. 1A). 
There were 11 (37%) patients who did not return for 
their initial TOC before day 8 to day 14 after treatment; 
however, they were then all negative (Table SI; Fig. 
1b). 
Antimicrobial resistance testing was performed on 
N. gonorrhoeae isolates from 25 of the 30 included 
patients. Isolates from 17 (68%) of these patients were 
ciprofloxacin-resistant; however, no isolate was resis-
tant to ceftriaxone (Table SI), or spectinomycin.
DISCUSSION 
The high level of antimicrobial resistance in N. gonorr-
hoeae is a public health problem worldwide. The inter-
nationally recommended first-line ESCs are the only 
remaining options for effective treatment of gonorrhoea 
in several settings (8, 14). However, the susceptibility 
to all the ESCs is decreasing and treatment failures of 
urogenital gonorrhoea have been identified using the 
oral ESC cefixime (6–8). Furthermore, Ohnishi et al. 
(15) recently described the first strain with high-level 
resistance to ceftriaxone, which most likely was rela-
ted to a treatment failure of pharyngeal gonorrhoea. 
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Accordingly, gonorrhoea may become untreatable in 
certain circumstances and especially in some settings. 
Appropriate verification/falsification of presumed 
clinical treatment failures needs to be emphasized 
worldwide. 
A more extensive use of TOC to assess treatment 
outcome is accordingly warranted. However, the use 
of TOC for N. gonorrhoeae is debated and the recom-
mendations vary for uncomplicated gonorrhoea. Centers 
for Disease Control and Prevention (CDC) (16) recom-
mend re-testing within 3 months rather than TOC for 
uncomplicated gonococcal infection, as a high number 
of positive cases after treatment may be re-infections 
(17, 18). The british Association of Sexual Health and 
HIV (bASHH; www.bashh.org/documents/3611) and 
The International Union against Sexually Transmitted 
Infections (IUSTI) (1) do not recommend the routine 
use of TOC for anogenital infections if a recommended 
treatment has been given. Indications for TOC are: per-
sistence of symptoms, re-exposure to infection, possible 
antimicrobial resistance, stipulated by national practice 
or in case of pharyngeal infections. Manavi et al. (19) 
also recommends TOC for pharyngeal infections be-
cause of higher rate of treatment failure. Accordingly, 
pharyngeal gonococcal infections, in particular, pose 
an additional problem because these can be difficult to 
treat (20–22), and are often asymptomatic, resulting in 
potential reservoirs for further transmission. 
NAATs are rapidly replacing culture for detection of 
N. gonorrhoeae, and for non-culture-based diagnostics, 
such as NAATs, adequate evidence-based recom-
mendations for appropriate time for TOC are lacking. 
One study has previously been published regarding 
appropriate time for TOC using NAAT for detection of 
N. gonorrhoeae. This study, by bachmann et al. (23), 
examined urine and patient-obtained vaginal swab 
specimens using ligase chain reaction (lCR). They 
found that all gonococcal DNA was absent from urine 
samples by day 6 (regardless of sex) and vaginal swabs 
by day 9, and concluded that TOC could be taken within 
14 days after appropriate treatment regardless of spe-
cimen. In the present study all individuals, except one, 
were negative within 2 weeks after treatment using an 
in-house porA pseudogene PCR. The remaining patient 
did not return before day 19 for his second TOC, but 
then had a negative TOC. Furthermore, 84% of the 
patients returning for their first TOC (within one week) 
were already negative. The present study using an in-
house porA pseudogene PCR (12, 13) fully supports 
the findings by Bachmann et al. (23). Accordingly, an 
appropriate time for TOC using NAATs for diagnosis 
of gonorrhoea seems to be 14 days after treatment. It 
is advantageous to avoid having a longer time before 
TOC, i.e. to reduce the risk of a positive TOC due to 
re-infection instead of treatment failure. 
This study also showed that 24% of the initial 50 
gonorrhoea patients did not return within 2 weeks for 
TOC despite strict instructions to return already after 
one week, and 16% never returned for TOC. Failure to 
return for TOC is a greater concern in cases where only 
molecular results are available and treatment outcome 
cannot be assessed due to lack of antimicrobial resis-
tance testing. Partner notification and close follow-up 
of the index patient was performed vigilantly in this 
study. 
The main limitations of the present study included 
that it was a low number of examined gonorrhoea 
patients, several patients did not return for TOC at 
requested time-points, and additional TOCs were not 
performed with short intervals (not possible in the rou-
tine diagnostics), as performed in the study by bachman 
et al. (23).
In Norway, the national recommendation for empirical 
first-line treatment of gonorrhoea remains ciprofloxacin 
(10). In the present study, 68% of the culture-positive 
patients were infected by a ciprofloxacin-resistant N. 
gonorrhoeae strain. Thus, the guidelines for empirical 
treatment should be changed immediately. This conclu-
sion is further supported by a few previous Norwegian 
publications (13, 24) as well as numerous international 
reports (25–29).
In conclusion, an appropriate time for TOC seems to 
be 14 days after appropriate treatment when an in-house 
porA pseudogene PCR is used for detection of N. go-
norrhoeae. Despite differences in sensitivity, this time 
for TOC is most probably similar using most NAATs 
(at least the DNA-based NAATs). TOC and re-testing 













































Fig. 1. (A) Number of positive patients, of the ones that returned within 7 
days for their first test-of-cure (TOC), following treatment of gonorrhoea. 
*Did not return before day 19 for the second TOC. (b) Number of positive 
patients, of the ones that returned after 8 or more days for their first TOC, 
following treatment of gonorrhoea.
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gilant follow-up of partners and index patients. Facing 
the threat of untreatable gonorrhoea, the selection and 
use of antimicrobials should be evidence-based and 
warrants timely surveillance programmes nationally and 
internationally. Accordingly, the Norwegian gonorrhoea 
treatment guidelines should be modified immediately 
based on the high prevalence of ciprofloxacin-resistant 
isolates. 
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